8-K: Current report filing
Published on June 1, 2018
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
June 1, 2018
NEOGENOMICS, INC.
(Exact name of registrant as specified in its charter)
Nevada |
001-35756 |
74-2897368 |
||
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(I.R.S. Employer
Identification No.)
|
||
12701 Commonwealth Drive, Suite 9, Fort Myers, Florida |
33913 |
|
(Address of principal executive offices) |
(Zip Code) |
|
(239) 768-0600
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
||
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
||
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
||
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
||
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 |
Other Events. |
On June 1, 2018, NeoGenomics, Inc. (the “Company”) issued a press release announcing a strategic alliance between the Company and Pharmaceutical Product Development, LLC (“PPD”), a leading global contract research organization. The Company will provide a wide range of lab testing services to support PPD's oncology clinical trial activities in the U.S., Europe and Asia. The press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01. |
Financial Statements and Exhibits. |
(a) |
Not applicable |
(b) |
Not applicable |
(c) |
Not applicable |
(d) |
Exhibits |
99.1 Press Release of NeoGenomics, Inc. dated June 1, 2018.
Exhibit Index
Exhibit No. |
Description |
|
99.1 |
||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
NEOGENOMICS, INC. |
|
By: |
/s/ Sharon A. Virag |
Sharon A. Virag |
|
Chief Financial Officer |
|
June 1, 2018 |
|